IRCM, INSERM, University Montpellier, ICM, Montpellier, France.
ICM, Institut Cancer Montpellier, Montpellier, France.
Radiat Oncol. 2019 Aug 9;14(1):142. doi: 10.1186/s13014-019-1351-8.
Biomarkers for predicting late normal tissue toxicity to radiotherapy are necessary to personalize treatments and to optimize clinical benefit. Many radiogenomic studies have been published on this topic. Conversely, proteomics approaches are not much developed, despite their advantages.
We used the isobaric tags for relative and absolute quantitation (iTRAQ) proteomic approach to analyze differences in protein expression levels in ex-vivo irradiated (8 Gy) T lymphocytes from patients with grade ≥ 2 radiation-induced breast fibrosis (grade ≥ 2 bf+) and patients with grade < 2 bf + after curative intent radiotherapy. Patients were selected from two prospective clinical trials (COHORT and PHRC 2005) and were used as discovery and confirmation cohorts.
Among the 1979 quantified proteins, 23 fulfilled our stringent biological criteria. Immunoblotting analysis of four of these candidate proteins (adenylate kinase 2, AK2; annexin A1; heat shock cognate 71 kDa protein; and isocitrate dehydrogenase 2) confirmed AK2 overexpression in 8 Gy-irradiated T lymphocytes from patients with grade ≥ 2 bf + compared with patients with grade < 2 bf+. As these candidate proteins are involved in oxidative stress regulation, we also evaluated radiation-induced reactive oxygen species (ROS) production in peripheral blood mononuclear cells from patients with grade ≥ 2 bf + and grade < 2 bf+. Total ROS level, and especially superoxide anion level, increased upon ex-vivo 8 Gy-irradiation in all patients. Analysis of NADPH oxidases (NOXs), a major source of superoxide ion in the cell, showed a significant increase of NOX4 mRNA and protein levels after irradiation in both patient groups. Conversely, only NOX4 mRNA level was significantly different between groups (grade ≥ 2 bf + and grade < 2 bf+).
These findings identify AK2 as a potential radiosensitivity candidate biomarker. Overall, our proteomic approach highlights the important role of oxidative stress in late radiation-induced toxicity, and paves the way for additional studies on NOXs and superoxide ion metabolism.
预测放疗后晚期正常组织毒性的生物标志物对于实现治疗个体化和优化临床获益非常必要。已有许多放射基因组学研究对此进行了探讨。然而,尽管蛋白质组学方法具有优势,但目前相关研究并不多。
我们采用同位素标记相对和绝对定量(iTRAQ)蛋白质组学方法,分析了根治性放疗后发生 2 级及以上放射性乳腺纤维化(2 级及以上 bf+)患者与 2 级以下 bf+患者的离体 8Gy 照射 T 淋巴细胞中蛋白质表达水平的差异。这些患者均来自两项前瞻性临床试验(COHORT 和 PHRC 2005),并被用作发现和验证队列。
在定量的 1979 种蛋白质中,有 23 种符合我们严格的生物学标准。对这 4 种候选蛋白(腺嘌呤激酶 2、AK2;膜联蛋白 A1;热休克同源 71kDa 蛋白;异柠檬酸脱氢酶 2)的免疫印迹分析证实,与 2 级以下 bf+患者相比,2 级及以上 bf+患者的离体 8Gy 照射 T 淋巴细胞中 AK2 表达增加。由于这些候选蛋白参与氧化应激调节,我们还评估了 2 级及以上 bf+和 2 级以下 bf+患者外周血单个核细胞在离体 8Gy 照射后的辐射诱导活性氧(ROS)产生情况。所有患者的总 ROS 水平,尤其是超氧阴离子水平,在离体 8Gy 照射后均增加。分析 NADPH 氧化酶(NOXs)——细胞中超氧阴离子的主要来源,结果显示,在两组患者中,NOX4mRNA 和蛋白水平在照射后均显著增加。然而,只有 NOX4mRNA 水平在组间存在显著差异(2 级及以上 bf+和 2 级以下 bf+)。
这些发现确定 AK2 为一种有潜力的放射敏感性候选生物标志物。总之,我们的蛋白质组学方法强调了氧化应激在晚期放射性毒性中的重要作用,并为进一步研究 NOXs 和超氧阴离子代谢铺平了道路。